February 28, 2015 2:30 AM ET


Company Overview of Koronis Pharma, Inc.

Company Overview

Koronis Pharma, Inc., a biotechnology company, develops antiviral therapeutics based on Viral Decay Acceleration mechanism. It develops KP-1461 for the treatment of HIV virus; and products for the treatment of antiviral infections. The company was founded in 1998 and is based in Seattle, Washington.

500 Union Street

Suite 835

Seattle, WA 98101

United States

Founded in 1998





Key Executives for Koronis Pharma, Inc.

Consulting Chief Medical Director and Clinical & Scientific Advisor
Member of Clinical Advisory Board and Clinical & Scientific Advisor
Member of Clinical Advisory Board and Clinical & Scientific Advisor
Clinical & Scientific Advisor
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
ProdiGene, Inc. United States
Genyous Life Sciences United States
OroGen Bio Sciences, Inc. United States
C2 Therapeutics, Inc. United States
Adaptive Symbiotic Technologies LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Koronis Pharma, Inc., please visit www.koronispharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.